Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Stilgenbauer

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Leukemia|October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemiaM Fürstenau, J Bahlo, A M Fink, et al.
Leukemia|May 3, 2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLLC Maurer, P Langerbeins, J Bahlo, et al.
Leukemia|December 3, 2016
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trialJ Edelmann, E Tausch, D A Landau, et al.
Leukemia|October 23, 2010
Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemiaM Shehata, D Demirtas, S Schnabl, et al.
Leukemia|February 23, 2018
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretationJ Malcikova, E Tausch, D Rossi, et al.
Leukemia|March 24, 2020
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsO Al-Sawaf, S Robrecht, J Bahlo, et al.
Leukemia|May 16, 2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.
Leukemia|June 22, 2013
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabA M Fink, S Böttcher, M Ritgen, et al.
Leukemia|October 25, 2016
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemiaG Lohmann, E Vasyutina, J Bloehdorn, et al.
Leukemia|July 27, 2017
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study groupO Al-Sawaf, S Robrecht, J Bahlo, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Leukemia|October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemiaM Fürstenau, J Bahlo, A M Fink, et al.
Leukemia|May 3, 2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLLC Maurer, P Langerbeins, J Bahlo, et al.
Leukemia|December 3, 2016
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trialJ Edelmann, E Tausch, D A Landau, et al.
Leukemia|October 23, 2010
Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemiaM Shehata, D Demirtas, S Schnabl, et al.
Leukemia|February 23, 2018
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretationJ Malcikova, E Tausch, D Rossi, et al.
Leukemia|March 24, 2020
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsO Al-Sawaf, S Robrecht, J Bahlo, et al.
Leukemia|May 16, 2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.
Leukemia|June 22, 2013
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabA M Fink, S Böttcher, M Ritgen, et al.
Leukemia|October 25, 2016
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemiaG Lohmann, E Vasyutina, J Bloehdorn, et al.
Leukemia|July 27, 2017
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study groupO Al-Sawaf, S Robrecht, J Bahlo, et al.
Pageof 10